Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

Investor Relations

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Events
News Releases
November 13, 2018
electroCore, Inc. Announces Third Quarter Financial Results
BASKING RIDGE, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three months and nine months ended September 30, 2018 .
October 30, 2018
electroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of trading on Tuesday,

Investor Contact

Investor Relations

Lynn Pieper Lewis
investors@electrocore.com